In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global IV and Oral Iron Drugs Market Report
The global IV and oral iron drugs market by revenue is expected to grow at a CAGR of 11.6% during the period 2021–2026.
The global IV and oral iron drugs market is expected to grow due to the prevalence of iron deficiency (ID). This deficiency is a highly widespread nutritional disorder, affecting around one-fourth of the global population, especially women and children. It is one of the predominant causes of anemia. Anemia accounts for around 9% of the total global disease burden. Several chronic diseases are frequently associated with iron deficiency anemia (IDA) such as chronic kidney disease (CKD), chronic heart failure, cancer, and inflammatory bowel diseases. As anemia is associated with chronic fatigue, diminished well-being, and impaired cognitive function, the treatment with oral and IV iron drugs reduces the need for blood transfusion in patients. Further, the WHO rates ID as the most common and widespread nutritional disorder globally, and its prevalence is expected to grow with the aging population and the incidence of various chronic disorders.
The following factors are likely to contribute to the growth of the IV and Oral Iron Drugs market during the forecast period:
• Strategic Collaborations & Licensing Opportunities
• Investigational Iron Drugs
• Increasing Availability of Branded Iron Therapeutics and Expanded Indication Approvals
The study considers the present scenario of the IV and Iron drugs market and its market dynamics for the period 2020?2026. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.
Global IV and Oral Iron Drugs Market Segmentation The global IV and Oral iron drugs market research report includes a detailed segmentation by route of administration, application, patient group, distribution, geography. Expected launches of branded IV iron drugs in new markets and expanded indication approvals for existing commercially available brands are the key factors influencing the growth of IV iron drugs. The increased uptake of branded IV drugs in the US and European countries is also expected to contribute significantly during the forecast period. Moreover, the rise in global medicine and healthcare expenditure and high-sensitivity, accuracy, easy, and convenient access to intravenous iron dosages is likely to drive the demand for IV iron drugs over the next few years.
The growing prevalence of chronic kidney disease (CKD) and nephrological disorders across the world is increasing the application of iron drugs at a faster rate, and the trend is likely to continue during the forecast period. Across the globe, one in five men and one in four women have CKD among people above 65 years of age. Hence, a high prevalence of renal failures, particularly in developing countries such as China and India, where the number of older adults is increasing, is expected to affect market growth. Approximately 70% of patients with CKD suffer from iron deficiencies, which can aggravate renal anemia. Therefore, iron therapy with IV & oral iron drugs is an essential treatment option for CKD patients.
Adults constitute over 81% share of the global IV and oral iron drugs market. Adults dominate the market due to the high incidence and prevalence of ID and IDA in the elderly population across the globe. CKD is relatively common among adults, with a prevalence rate of up to 13%. With the increase in the incidence of diabetes and hypertension, CKD patients are likely to grow, thereby increasing the demand for iron drugs. Also, the percentage of the geriatric population is increasing at a significant rate worldwide, which is a key factor driving the growth of the segment.
Hospital pharmacies offer iron drugs with adequate discounts and rebates. Innovations in hospital pharmacy practice have led to the emergence of pharmacists working in community health services, aged care facilities, rehabilitation facilities, and general practice clinics. Such practices of hospital pharmacists are further driving the uptake of iron drugs via hospital pharmacies.
INSIGHTS BY VENDORS Vifor Pharma and Daiichi Sankyo Company are the leading players in the global IV and oral iron drugs market. However, AMAG Pharmaceuticals, PHARMACOSMOS, Sanofi, Allergan, Akebia Therapeutics, and Shield Therapeutics are other prominent players in the market with notable shares. Vendors are competing on a wide variety of factors such as innovations, marketing strategies, and distribution channels. Global companies have a wide geographic footprint, diversified product portfolio, and a strong focus on product innovation, R&D, and business expansion activities. Key players are expected to drive sales and margin growth in their business by expanding sales organization, maintaining technology leadership through R&D, and continuing to build clinical evidence to support the benefits of the products as well as services.
• Vifor Pharma
• Daiichi Sankyo Company
• AZAD Pharma
• Ciron Drugs & Pharmaceuticals
• Rockwell Medical
• Salveo Lifecare
• Sunny Pharmaceutical
INSIGHTS BY GEOGRAPHY The North American IV and oral iron drugs market share is expected to witness promising growth during the forecast period. The high uptake of branded iron drugs is one of the major reasons for strong growth. Vendors offering branded drugs are generating significantly higher revenue from the US than other markets. Also, the increased healthcare spending in the US and Canada is further contributing to the growth of the market. The prevalence of ID is likely to increase during the forecast period as the number of people with conditions such as CKD, CHF, IBD, and uterine bleeding is increasing in the country. Moreover, according to the United States Renal Data System (USRDS), the number of people suffering from CKD in the US alone was around 30 million people in 2020. A stressful lifestyle and the rise in chronic conditions are factors for the increase in the number of people with ID in the region.
• North America
o South Korea
• Latin America
• Middle East & Africa
o Saudi Arabia
o South Africa
KEY QUESTIONS ANSWERED 1. What is the IV and oral iron drugs market size and growth rate during the forecast period?
2. What is the impact of COVID-19 on the intravenous iron drugs market share?
3. Which regions are expected to observe high revenues for IV and oral drugs during the forecast period?
4. Who are the notable market players in the global IV and oral iron drugs market?
5. What are the opportunities and threats faced by key vendors in the market?
Our reports have been used by over 10K customers, including:
The propelling factors for the growth of the apheresis market include the increasing number of diseases, a rise in the demand for blood components and associated safety, technological advancement in the development of new apheresis techniques, and rise in the reimbursement policies and funding for apheresis procedures. With the increasing...
296 pages •
By The Business Research Company
• Mar 2021
Vascular Endothelial Growth Factor (VEGF) Inhibitor Global Market Opportunities And Strategies To 2030: COVID 19 Impact And Recovery provides the strategists, marketers and senior management with the critical information they need to assess the global vascular endothelial growth factor (VEGF) inhibitor market. Description: Where...
Belgium - Healthcare, Regulatory and Reimbursement Landscape
The analyst has released its latest report: “Belgium - Healthcare, Regulatory and Reimbursement Landscape”.The report is an essential source of information on analysis of healthcare, regulatory, and reimbursement landscape in...
China - Healthcare, Regulatory and Reimbursement Landscape
The analyst has released its latest report “China - Healthcare, Regulatory and Reimbursement Landscape”.The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in China.
India - Healthcare, Regulatory and Reimbursement Landscape Summary The analyst has released its latest report: “India - Healthcare, Regulatory and Reimbursement Landscape”.The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in India. It...
The market is primarily driven by the growing prevalence of chronic diseases such as diabetes, respiratory diseases and cancer. Furthermore, the growing geriatric population and technological advances in drug delivery systems is projected to boost market growth over the forecast period. Moreover, expanding applications of drug device combination...
292 pages •
By The Business Research Company
• Mar 2021
Ultrasound Devices And Equipment Global Market Opportunities And Strategies To 2030: COVID-19 Impact And Recovery provides the strategists, marketers and senior management with the critical information they need to assess the global ultrasound devices and equipment market as it emerges from the COVID 19 shut down. Description: Where...
The global healthcare gamification market is expected to reach US$35,982.7 million in 2027 from US$ 3,072.5 million in 2019. The market is estimated to grow with a CAGR of 36.2% from 2020-2027. The growth of the market is attributed to factors such as increasing adoption of gamification in healthcare and rise in number of technology launches....
The artificial intelligence (AI) in healthcare diagnosis market was valued at US$ 3,639.02 million in 2019 and is projected to reach US$ 66,811.97 million by 2027; it is expected to grow at a CAGR of 44.0% during 2020–2027. The growth of the market is mainly attributed to factors such rising adoption of AI in disease identification and diagnosis,...
The global tele-intensive care unit market was valued at USD 3,160 million in 2020 and is expected to reach USD 8,950 million by 2026, registering a CAGR of about 19% over the forecast period. As the COVID?19 pandemic continues to expand throughout the world, innovative methods are required to involve residents in the care of critically...
Surgical Procedures Performed
Medical Technology Density
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.